Drugs / 89Zr-bevacizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01859234 | May 2013 → May 2014 | plasma cell myeloma | University Medical Center Groningen | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-bevacizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01859234 ↗ |
| Action | Inhibit | “Blocking VEGF itself can be obtained by means of bevacizumab” NCT01859234 ↗ |
| Modality | Monoclonal antibody | “bevacizumab, a recombinant, humanised monoclonal antibody that binds to all isoforms of human VEGF with high affinity.” NCT01859234 ↗ |